CAC
CLVS

Cowen and Company’s Clovis Oncology, Inc. CLVS Stock Holding History

Cowen and Company’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-41,492
Closed -$185K – 845
2021
Q3 		$185K Buy
+41,492
New +$200K 0.01% 269
2020
Q2 		– Sell
-465,132
Closed -$2.96M – 499
2020
Q1 		$2.96M Buy
+465,132
New +$3.73M 0.68% 31

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cowen and Company's CLVS Position: Q4 2021 in Review

Cowen and Company sold out of Clovis Oncology, Inc. (CLVS) in Q4 2021, closing a stake of 41,492 shares — an estimated $185K sold.

Cowen and Company first reported a position in CLVS in Q1 2020 and held it in 2 quarters. The position peaked at $2.96M in Q1 2020. 153 funds tracked by Wall St. Rank hold CLVS as of Q4 2021.

  • Cowen and Company reported no remaining Clovis Oncology, Inc. position as of Q4 2021 after selling out during the quarter.
  • Cowen and Company sold 41,492 Clovis Oncology, Inc. shares in Q4 2021, an estimated $185K.
  • Cowen and Company first reported a position in Clovis Oncology, Inc. in Q1 2020 and held it in 2 quarters.
  • Cowen and Company's Clovis Oncology, Inc. position peaked at $2.96M in Q1 2020.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2021.

Based on Cowen and Company's 13F filing for Q4 2021, filed 14 Feb 2022.